Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2023)

4D Molecular Therapeutics (FDMT) has disclosed Other financing activities for 4 consecutive years, with $260000.0 as the latest value for Q2 2023.

  • Quarterly Other financing activities rose 128.07% to $260000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $329000.0 through Jun 2024, down 24.71% year-over-year, with the annual reading at $468000.0 for FY2022, N/A changed from the prior year.
  • Other financing activities for Q2 2023 was $260000.0 at 4D Molecular Therapeutics, up from $69000.0 in the prior quarter.
  • The five-year high for Other financing activities was $946000.0 in Q1 2021, with the low at -$946000.0 in Q4 2021.
  • Average Other financing activities over 4 years is $74272.7, with a median of $114000.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 149.47% in 2022, while the deepest fall reached 74.0% in 2022.
  • Over 4 years, Other financing activities stood at -$348000.0 in 2020, then plummeted by 171.84% to -$946000.0 in 2021, then skyrocketed by 149.47% to $468000.0 in 2022, then crashed by 44.44% to $260000.0 in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $260000.0, $69000.0, and $468000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.